Nautilus Q2 net loss $15.8M; cash runway extended through 2025-2026

Nautilus Biotechnology, Inc.

2023-Q2 EPS reported -$0.25

Operating expenses $19.0M, up 23% YoY from $15.5M driven by product development headcount.
Net loss $15.8M vs $14.7M in Q2 2022; company pre-revenue, still in development stage.
Cash, equivalents, and investments $286.7M as of June 30, 2023; CEO says funds operations into 2026.
CEO reports progress integrating sample prep, probes, chips, instrument, and software for commercial launch.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Nautilus Biotechnology, Inc. reported second quarter ended June 30, 2023 results: net income $15.8 million.

Period: second quarter ended June 30, 2023
Net income: $15.8 million
Result: reported results

Exact text from the filing

Net loss was $15.8 million for the second quarter of 2023

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Nautilus Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001808805-23-000066

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.